Medicus Pharma Ltd MDCX 深 滬
交易中 01-29 11:02:09 美东时间
1.20
+0.020
+1.69%
華盛通- 最 高1.2257
- 今 開1.17
- 成交量 12.44万股
- 最 低 1.16
- 昨 收 1.18
- 總市值 2137.96万
- 52周最高 8.94
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 1.14
- 委 比 98.74%
- 總股本 1781.63万
- 歷史最高 8.94
- 量 比 1.69
- 振 幅 5.57%
- 歷史最低 1.14
- 每 手 1
- 風險率 1.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BUZZ-U.S. STOCKS ON THE MOVE-Autodesk, Teledyne, Alphabet
BUZZ-U.S. STOCKS ON THE MOVE-Autodesk, Teledyne, Alphabet Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes continued to push higher on Thursday, inching tow
01-23 00:02
BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital
BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to extend gains on Thu
01-22 22:11
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
<p>Medicus Pharma Ltd. celebrates one year as a Nasdaq-listed company by ringing the Nasdaq Opening Bell on January 22, 2026. The company has advanced its pipeline, including SkinJect for basal cell carcinoma and Teverelix for prostate cancer, with Phase 2 data nearing completion and potential partnering opportunities. Medicus emphasizes disciplined execution and AI-driven clinical development strategies to address significant unmet medical needs...
01-20 12:30
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
Medicus Pharma announced the acceptance of its abstract on Teverelix, a long-acting GnRH antagonist, for presentation at the 2026 AACE Annual Meeting. The abstract highlights Phase 1 study results demonstrating rapid hormone suppression, stable bone markers, and favorable safety profiles in healthy women. These findings support potential use in endometriosis, with plans for a Phase 2 study in the UAE. Additionally, SkinJect™, a microneedle delive...
01-12 12:30
Medicus Pharma To Present Data At Biotech Showcase 2026
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics
01-05 20:35
Medicus Pharma Enters Equity Distribution Agreement, Launches ~$15.35M At-The-Market Equity Program With Maxim And Yorkville Securities
On December 29, 2025, Medicus Pharma Ltd. (the "Company") entered into an Equity Distribution Agreement (the "Agreement") with Maxim Group LLC ("Maxim") and Yorkville Securities, LLC ("Yorkville Securities" and together
2025-12-30 22:30
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:MDCX) with a Buy and maintains $27 price target.
2025-12-15 21:16
Medicus Pharma Elevates President Carolyn Bonner to CFO as Co-Founder Jim Quinlan Steps Down for Health Reasons
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics
2025-12-01 20:37
Medicus Pharma Seeks Fast-Track FDA Voucher for New Skin Cancer Treatment
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
2025-11-17 20:35
